SymBio Pharmaceuticals Limited

3:30 PM - 3:45 PM (EDT), Monday, June 5, 2023 ・ Session Room 104C
SymBio Pharmaceuticals Limited is a fully integrated, commercial-stage specialty pharmaceutical company with therapeutic focus on oncology/hematology, infectious diseases, and neurodegenerative diseases. SymBio has been committed to moving forward into unexplored underserved therapeutic areas where urgent and unmet medical needs exist since its establishment in 2005. Our experts with extensive experience in drug discovery and evaluation globally navigate through information about new drugs from bio-ventures, laboratories, and pharmaceutical companies, selecting with discerning capacity the most promising drug candidates that are likely to meet compelling medical needs. Our Scientific Advisory Board (SAB) is comprised of leading clinicians and scientists who provide impartial screening of potential drug candidates before they are brought into our pipeline.
Tokyo Stock Exchange Growth Market
Company Type:
Publicly Traded Company
Company HQ State:
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Multiple Therapeutics
Lead Product in Development:
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Placeholder Photo
Head of Business Development
SymBio Pharmaceuticals Limited
Placeholder Photo
Chief Scientific Officer and Head of Translational Research
SymBio Pharmaceuticals Limited